Mutational analysis differentiating sporadic carcinomas from colitis-associated colorectal carcinomas.
Colitis-associated carcinoma
Conventional carcinoma
Mutation
Non-conventional carcinoma
Sporadic carcinoma
Ulcerative colitis
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
10 Oct 2024
10 Oct 2024
Historique:
received:
28
06
2024
accepted:
27
09
2024
medline:
11
10
2024
pubmed:
11
10
2024
entrez:
10
10
2024
Statut:
epublish
Résumé
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that is associated with increased risk of developing colitis-associated carcinoma (CAC). The genetic profile of CACs is fairly similar to the sporadic colorectal carcinomas (sCRCs), although showing certain differences in the timing and sequence of alterations that contribute to carcinogenesis. Also, both cancer types typically show a strong histological resemblance, which complicates the pathologists' diagnosis. Due to the different clinical consequences, it is of utmost importance to categorize the corresponding cancer type correctly. In this study, we determined the mutation profiles of 64 CACs and sCRCs in the hotspot regions of 50 cancer-associated genes and compared them to 29 controls to identify genetic gene variants that can facilitate the pathologists' diagnosis. Pearson Chi-Square or Fisher's exact tests were used for statistical analyses. We found that sCRCs tend to mutate more frequently in APC and PIK3CA genes than CACs and that mainly males were affected. Our CAC cohort identified the KRAS G12D mutation as group-specific variant that was not detected in the sCRCs. When separating conventional from non-conventional CACs, it was discovered that the conventional type shows significantly more mutations for ATM. Taken together, our data highlights genetic differences between sCRC and CAC and enables the possibility to utilize specific gene alterations to support the pathologist's diagnosis.
Sections du résumé
BACKGROUND
BACKGROUND
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that is associated with increased risk of developing colitis-associated carcinoma (CAC). The genetic profile of CACs is fairly similar to the sporadic colorectal carcinomas (sCRCs), although showing certain differences in the timing and sequence of alterations that contribute to carcinogenesis. Also, both cancer types typically show a strong histological resemblance, which complicates the pathologists' diagnosis. Due to the different clinical consequences, it is of utmost importance to categorize the corresponding cancer type correctly.
METHODS
METHODS
In this study, we determined the mutation profiles of 64 CACs and sCRCs in the hotspot regions of 50 cancer-associated genes and compared them to 29 controls to identify genetic gene variants that can facilitate the pathologists' diagnosis. Pearson Chi-Square or Fisher's exact tests were used for statistical analyses.
RESULTS
RESULTS
We found that sCRCs tend to mutate more frequently in APC and PIK3CA genes than CACs and that mainly males were affected. Our CAC cohort identified the KRAS G12D mutation as group-specific variant that was not detected in the sCRCs. When separating conventional from non-conventional CACs, it was discovered that the conventional type shows significantly more mutations for ATM.
CONCLUSIONS
CONCLUSIONS
Taken together, our data highlights genetic differences between sCRC and CAC and enables the possibility to utilize specific gene alterations to support the pathologist's diagnosis.
Identifiants
pubmed: 39390564
doi: 10.1186/s12964-024-01856-8
pii: 10.1186/s12964-024-01856-8
doi:
Substances chimiques
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
Adenomatous Polyposis Coli Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
483Informations de copyright
© 2024. The Author(s).
Références
Kucharzik T, Dignass A, Atreya R, Bokemeyer B, Esters P, Herrlinger K, et al. Aktualisierte S3-Leitlinie colitis ulcerosa (Version 6.1) – Februar 2023 – AWMF-Registriernummer: 021 – 009. Z Gastroenterol. 2023;61:1046–134. https://doi.org/10.1055/a-2060-0935 .
doi: 10.1055/a-2060-0935
pubmed: 37579791
GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;5:17–30. https://doi.org/10.1016/S2468-1253(19)30333-4 .
doi: 10.1016/S2468-1253(19)30333-4
Adams SM, Bornemann PH. Ulcerative colitis. Am Fam Physician. 2013;87:699–705.
pubmed: 23939448
Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22:299–306. https://doi.org/10.1101/gr.126516.111 .
doi: 10.1101/gr.126516.111
pubmed: 22009989
pmcid: 3266037
Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22:292–8. https://doi.org/10.1101/gr.126573.111 .
doi: 10.1101/gr.126573.111
pubmed: 22009990
pmcid: 3266036
Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–35. https://doi.org/10.1136/gut.48.4.526 .
doi: 10.1136/gut.48.4.526
pubmed: 11247898
pmcid: 1728259
Selinger CP, Andrews JM, Titman A, Norton I, Jones DB, McDonald C, et al. Long-term follow-up reveals low incidence of colorectal cancer, but frequent need for resection, among Australian patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:644–50. https://doi.org/10.1016/j.cgh.2013.05.017 .
doi: 10.1016/j.cgh.2013.05.017
pubmed: 23707778
Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982–1018. https://doi.org/10.1016/j.crohns.2013.09.016 .
doi: 10.1016/j.crohns.2013.09.016
pubmed: 24184171
Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6:74. https://doi.org/10.1038/s41572-020-0205-x .
doi: 10.1038/s41572-020-0205-x
pubmed: 32913180
Lang-Schwarz C, Adler W, Geppert M, Seitz G, Sterlacci W, Falkeis-Veits C, et al. Sporadic adenoma or ulcerative colitis associated neoplasia? The endoscopist’s information has an impact on diagnosis and patient management. Pathol Res Pract. 2020;216:153162. https://doi.org/10.1016/j.prp.2020.153162 .
doi: 10.1016/j.prp.2020.153162
pubmed: 32916446
Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011;140:1807–16. https://doi.org/10.1053/j.gastro.2011.01.057 .
doi: 10.1053/j.gastro.2011.01.057
pubmed: 21530747
Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett. 2014;345:235–41. https://doi.org/10.1016/j.canlet.2013.07.032 .
doi: 10.1016/j.canlet.2013.07.032
pubmed: 23941831
Leslie A, Carey FA, Pratt NR, Steele RJC. The colorectal adenoma-carcinoma sequence. Br J Surg. 2002;89:845–60. https://doi.org/10.1046/j.1365-2168.2002.02120.x .
doi: 10.1046/j.1365-2168.2002.02120.x
pubmed: 12081733
Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449–60. https://doi.org/10.1056/NEJMra0804588 .
doi: 10.1056/NEJMra0804588
pubmed: 20018966
pmcid: 2843693
Digestive system tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2019.
Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754–60. https://doi.org/10.1093/bioinformatics/btp324 .
doi: 10.1093/bioinformatics/btp324
pubmed: 19451168
pmcid: 2705234
Dregelies T, Haumaier F, Sterlacci W, Backert S, Vieth M. Detection of Fusobacterium nucleatum in patients with Colitis-Associated Colorectal Cancer. Curr Microbiol. 2023;80:293. https://doi.org/10.1007/s00284-023-03398-7 .
doi: 10.1007/s00284-023-03398-7
pubmed: 37468740
pmcid: 10356651
Harpaz N, Goldblum JR, Shepherd NA, Riddell RH, Rubio CA, Vieth M, et al. Colorectal dysplasia in chronic inflammatory bowel disease: a contemporary consensus classification and interobserver study. Hum Pathol. 2023;138:49–61. https://doi.org/10.1016/j.humpath.2023.05.008 .
doi: 10.1016/j.humpath.2023.05.008
pubmed: 37247824
Gui X, Iacucci M, Ghosh S, Ferraz JGP, Lee S. Revisiting the distinct histomorphologic features of inflammatory bowel disease-associated neoplastic precursor lesions in the SCENIC and post-DALM era. Hum Pathol. 2020;100:24–37. https://doi.org/10.1016/j.humpath.2020.04.010 .
doi: 10.1016/j.humpath.2020.04.010
pubmed: 32387105
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–32. https://doi.org/10.1056/NEJM198809013190901 .
doi: 10.1056/NEJM198809013190901
pubmed: 2841597
Aghabozorgi AS, Bahreyni A, Soleimani A, Bahrami A, Khazaei M, Ferns GA, et al. Role of adenomatous polyposis coli (APC) gene mutations in the pathogenesis of colorectal cancer; current status and perspectives. Biochimie. 2019;157:64–71. https://doi.org/10.1016/j.biochi.2018.11.003 .
doi: 10.1016/j.biochi.2018.11.003
pubmed: 30414835
Robles AI, Traverso G, Zhang M, Roberts NJ, Khan MA, Joseph C, et al. Whole-exome sequencing analyses of inflammatory bowel Disease-Associated Colorectal cancers. Gastroenterology. 2016;150:931–43. https://doi.org/10.1053/j.gastro.2015.12.036 .
doi: 10.1053/j.gastro.2015.12.036
pubmed: 26764183
Yaeger R, Shah MA, Miller VA, Kelsen JR, Wang K, Heins ZJ, et al. Genomic alterations observed in Colitis-Associated Cancers are distinct from those found in sporadic colorectal cancers and vary by type of inflammatory bowel disease. Gastroenterology. 2016;151:278–e2876. https://doi.org/10.1053/j.gastro.2016.04.001 .
doi: 10.1053/j.gastro.2016.04.001
pubmed: 27063727
Baker A-M, Cross W, Curtius K, Al Bakir I, Choi C-HR, Davis HL, et al. Evolutionary history of human colitis-associated colorectal cancer. Gut. 2019;68:985–95. https://doi.org/10.1136/gutjnl-2018-316191 .
doi: 10.1136/gutjnl-2018-316191
pubmed: 29991641
Rajamäki K, Taira A, Katainen R, Välimäki N, Kuosmanen A, Plaketti R-M, et al. Genetic and epigenetic characteristics of inflammatory bowel Disease-Associated Colorectal Cancer. Gastroenterology. 2021;161:592–607. https://doi.org/10.1053/j.gastro.2021.04.042 .
doi: 10.1053/j.gastro.2021.04.042
pubmed: 33930428
AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017;7:818–31. https://doi.org/10.1158/2159-8290.CD-17-0151 .
doi: 10.1158/2159-8290.CD-17-0151
Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD, et al. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology. 1993;104:1633–9. https://doi.org/10.1016/0016-5085(93)90639-T .
doi: 10.1016/0016-5085(93)90639-T
pubmed: 8500720
Iwaya M, Ota H, Nakajima T, Uehara T, Riddell R, Conner J. Most colitis associated carcinomas lack expression of LGR5: a preliminary study with implications for unique pathways of carcinogenesis compared to sporadic colorectal carcinoma. BMC Cancer. 2021;21:119. https://doi.org/10.1186/s12885-021-07835-3 .
doi: 10.1186/s12885-021-07835-3
pubmed: 33541282
pmcid: 7863293
Kamarádová K, Vošmiková H, Rozkošová K, Ryška A, Tachecí I, Laco J. Morphological, immunohistochemical and molecular features of inflammatory bowel disease associated colorectal carcinoma and associated mucosal lesions - single institution experience. Pathol Res Pract. 2019;215:730–7. https://doi.org/10.1016/j.prp.2019.01.010 .
doi: 10.1016/j.prp.2019.01.010
pubmed: 30679085
Enea D, Lauwers G, Svrcek M. Dysplasies Conventionnelles et non conventionnelles compliquant les maladies inflammatoires chroniques de l’intestin. [Conventional and non-conventional dysplasia in patients with inflammatory bowel disease]. Ann Pathol. 2023;43:180–91. https://doi.org/10.1016/j.annpat.2023.02.006 .
doi: 10.1016/j.annpat.2023.02.006
pubmed: 36906454
Rubinstein MR, Baik JE, Lagana SM, Han RP, Raab WJ, Sahoo D, et al. Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator annexin A1. EMBO Rep. 2019. https://doi.org/10.15252/embr.201847638 .
doi: 10.15252/embr.201847638
pubmed: 30833345
pmcid: 6446206
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67. https://doi.org/10.1016/0092-8674(90)90186-I .
doi: 10.1016/0092-8674(90)90186-I
pubmed: 2188735
Takeda K, Koi M, Okita Y, Sajibu S, Keku TO, Carethers JM. Fusobacterium nucleatum load correlates with KRAS Mutation and Sessile Serrated Pathogenesis in Colorectal Adenocarcinoma. Cancer Res Commun. 2023;3:1940–51. https://doi.org/10.1158/2767-9764.CRC-23-0179 .
doi: 10.1158/2767-9764.CRC-23-0179
pubmed: 37772997
pmcid: 10530411